TY - JOUR KW - Non-invasive test KW - fibroscan KW - elastography KW - compensated advanced chronic liver disease KW - diagnostic accuracy PB - Elsevier BV ID - discovery10192883 N2 - Background & Aims: Agile scores, including liver stiffness measurements (LSM) and routine clinical/laboratory biomarkers, have been developed for advanced fibrosis (F?3) and cirrhosis (F4), respectively, in patients with metabolic dysfunction-associated steatotic liver disease (MASLD). We independently validated the diagnostic accuracy of these scores in MASLD, alcohol-related liver disease (ALD) and chronic hepatitis B or C (CHB/C) and assessed them in clinical algorithms with FIB-4 and LSM. // Methods: We included 4,243 patients (MASLD: 912, ALD: 386, CHB: 597, CHC: 2,348) with LSM, liver biopsy and laboratory tests within 6 months. FIB-4, Agile 3+ and Agile 4 scores were calculated. // Results: For F?3, the diagnostic accuracy of Agile 3+ and LSM were similar in MASLD (AUC: 0.86 vs. 0.86, p = 0.831) and ALD (0.92 vs. 0.94, p = 0.123). For cirrhosis, Agile 4 was similar to LSM in MASLD (0.89 vs. 0.90, p = 0.412) and ALD (0.94 vs. 0.95, p = 0.513). Agile 3+/4 performed worse than LSM in CHB/C. Using predefined dual thresholds of 90% sensitivity/specificity, correct classification rates in MASLD were 66% vs. 61% using Agile 3+ vs. LS dual cut-offs and 71% vs. 67% in ALD, respectively. When using Agile 3+ or LSM as a second step after FIB-4 >1.3, correct classification rates were higher with Agile 3+ than LSM, both for MASLD (75% vs. 71%) and ALD (76% vs. 72%), with fewer indeterminate results. Positive agreement of LSM and Agile 3+/4 significantly increased the specificity of a diagnosis of advanced fibrosis/cirrhosis. // Conclusion: Agile 3+ and Agile 4 have equal diagnostic accuracy with LSM in both MASLD and ALD but result in fewer indeterminate results. Sequential use of FIB-4 and Agile 3+/4 or concurrent Agile 3+/4 and LSM can be used to further optimize F?3 diagnosis. EP - 599 AV - restricted Y1 - 2024/10// TI - Agile scores in MASLD and ALD: External validation and their utility in clinical algorithms A1 - Papatheodoridi, Margarita A1 - De Ledinghen, Victor A1 - Lupsor-Platon, Monica A1 - Bronte, Fabrizio A1 - Boursier, Jerome A1 - Elshaarawy, Omar A1 - Marra, Fabio A1 - Thiele, Maja A1 - Markakis, Georgios A1 - Payance, Audrey A1 - Brodkin, Edgar A1 - Castera, Laurent A1 - Papatheodoridis, George A1 - Krag, Aleksander A1 - Arena, Umberto A1 - Mueller, Sebastian A1 - Cales, Paul A1 - Calvaruso, Vincenza A1 - Delamarre, Adele A1 - Pinzani, Massimo A1 - Tsochatzis, Emmanuel A JF - Journal of Hepatology SN - 0168-8278 UR - http://dx.doi.org/10.1016/j.jhep.2024.05.021 N1 - This version is the author accepted manuscript. For information on re-use, please refer to the publisher's terms and conditions. IS - 4 SP - 590 VL - 81 ER -